SLC5A2 and type 2 diabetes mellitus: According to a systematic review by Scheen [50], SGLT-2 inhibitors and metformin combination therapy showed reduction in HbA1c (-0.60 and -0.54), FBG (-1.37 and -1.37), body weight (-2.23 and -2.16) in Asian vs. non-Asian individuals with T2D.